

WELCOME TO THE OXFORD TECHNOLOGY VCTS SHAREHOLDER PRESENTATION 2021

IN ATTENDANCE TODAY

VCT DIRECTORS – ALEX STARLING, RICHARD ROTH,
ROBIN GOODFELLOW AND DAVID LIVESLEY

OXFORD TECHNOLOGY MANAGEMENT TEAM

LUCIUS CARY, ANDREA MICA AND JOANNE HOAREAU

OXFORD TECHNOLOGY VCTS' SHAREHOLDER PRESENTATION

WEDNESDAY 28 JULY, 2PM



oxford
technology



AGENDA

- Oxford Technology Presentation
- Select Presentation Video
- Scancell Presentation Video
- OT2 VCT Strategy Presentation
- OT4 VCT Strategy Presentation
- OT VCT Strategy Presentation
- OT3 VCT Strategy Presentation
- Q&A

FY 2020/2021 NAV, DIVIDENDS, TOTAL RETURN

	OT1	OT2	OT3	OT4
Launch year	1997	2000	2002	2004
NAV/share p - Feb 21	49.7	24.8	42.2	26.4
Earnings/share p	5.0	(3.0)	(27.4)	(4.7)
Dividends for year p	0	0	0	5.0
Dividends to date p	55.0	22.5	36.0	48.0
Total return/share p – Feb 21	104.7	47.3	78.2	74.4
Total return/share p - May 21	100.6	49.7	80.4	78.8
Total return/share incl. tax relief	120.6	69.7	100.4	118.8



INVESTMENTS AND DISPOSALS

Disposals to June 2021

Castleton Technology OT4

June 2020: MRI Software completes acquisition of Castleton Technology plc. OT4 received £832k

Scancell

OT1 sold £109k to Feb 21 + £40k to May 21

OT3 sold £100k to Feb 21

Ixaris

June 2021: OT3 announced that a sale had been agreed for Ixaris to Nium. This is due to complete in the Autumn.


OT3 will receive £680k initially with a further sum of £121k expected within 3 years.

No investments made in financial year 20/21

Investments to June 2021

OT1 - £90k investment into Arecor Therapeutics Plc in June 2021


IXARIS



- Major supplier of payment systems for the travel sector
- Rollercoaster period which saw an offer for purchase withdrawn in December 2019 (Thomas Cook administration related)
- COVID-19 hit causing sales to fall by 95%
- Sale agreed on 7 June 2021 to Singapore based company Nium Plc – completion awaiting regulatory approval



SCANCELL



- Share price graph shows fluctuations in price.
- Progress continues on cancer related programmes.
- Scancell now also developing new coronavirus vaccine (COVIDITY) in collaboration with Centre for Research on Global Virus Infections and the new Biodiscovery Institute at the University of Nottingham.



STL MANAGEMENT – SELECT TECHNOLOGY

selectec




- Sales and distribution of software for managing scanners and printer devices
- Select has created a network of distribution channels
- 12 months sales to June 2021 £4.7m.
- Has been affected by COVID-19 but sales are recovering



oxford
technology

IMMBIO



- Not successful in winning grants so far (failed on 3)
- On-going discussion with licensee and potential partners
- Covid-19: Requirement for better vaccine – no funding partner yet



ARECOR



- Excellent clinical trial results show the Arecor insulin has best in class profile
- Partnership with Hikma in anti-infectives
- Arestat - 7 feasibility and 2 active milestone and royalty bearing license agreements
- June 2021 – Floated on AIM as Arecor Therapeutics PLC





THANK YOU

WWW.OXFORDTECHNOLOGYVCT.COM